UK & Europe

The United Kingdom and continental Europe.
Biologics

Cytokinetics aficamten data show structural heart benefits in HCM

New analyses from ACACIA-HCM and MAPLE-HCM presented at ESC 2026 strengthen aficamten's case across both obstructive and non-obstructive HCM subtypes.
New analyses from ACACIA-HCM and MAPLE-HCM presented at ESC 2026 strengthen aficamten's case across both obstructive and non-obstructive HCM subtypes.
The Biotech Times Editorial Team  · 
Biologics

Insulinova partners San Raffaele to test encapsulated beta cells

Insulinova will fund OSR-led research combining stem cell-derived beta cells with Austrianova's Cell-in-a-Box encapsulation platform to pursue immunosuppression-free
Insulinova will fund OSR-led research combining stem cell-derived beta cells with Austrianova's Cell-in-a-Box encapsulation platform to pursue immunosuppression-free
The Biotech Times Editorial Team  · 
Biologics

AskBio presents GenePHIT Phase 2 baseline data at ESC 2026

AskBio's umiposgene parvec heart failure gene therapy trial enrolled over 170 patients across 64 sites; efficacy data are expected in H1 2027.
AskBio's umiposgene parvec heart failure gene therapy trial enrolled over 170 patients across 64 sites; efficacy data are expected in H1 2027.
The Biotech Times Editorial Team  · 
Diagnostics

Philips and Imricor launch combined cardiac iMR lab solution

The partners have commercialised a 1.5T MRI-based interventional lab for cardiac ablation, removing reliance on X-ray fluoroscopy in CE-marked markets.
The partners have commercialised a 1.5T MRI-based interventional lab for cardiac ablation, removing reliance on X-ray fluoroscopy in CE-marked markets.
The Biotech Times Editorial Team  · 
Biologics

Amarin REDUCE-IT legacy analysis suggests durable CV benefit after IPE

A post hoc analysis of REDUCE-IT, presented at ESC 2026, suggests icosapent ethyl's cardiovascular benefit may persist years after treatment stops in adherent
A post hoc analysis of REDUCE-IT, presented at ESC 2026, suggests icosapent ethyl's cardiovascular benefit may persist years after treatment stops in adherent
The Biotech Times Editorial Team  · 
Biologics
Diagnostics

IBA swings to profit in H1 2026 as proton therapy orders surge

The Belgian particle accelerator group posted a €9.3m net profit in H1 2026, reversing a prior-year loss, with proton therapy order intake more
The Belgian particle accelerator group posted a €9.3m net profit in H1 2026, reversing a prior-year loss, with proton therapy order intake more
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science
Biologics

hVIVO acquires CRS Berlin to enter dermatology and women's health

hVIVO has bought the Berlin-based Phase I/II unit for a nominal upfront fee plus a revenue-linked earnout capped at roughly €6 million.
hVIVO has bought the Berlin-based Phase I/II unit for a nominal upfront fee plus a revenue-linked earnout capped at roughly €6 million.
The Biotech Times Editorial Team  · 
Regulatory Science
Biologics

INmune Bio files EMA packages for Ebstrocel in rare skin disease

INmune Bio has submitted an orphan drug designation application and pre-MAA scientific advice package to the EMA for its cell therapy Ebstrocel in RDEB.
INmune Bio has submitted an orphan drug designation application and pre-MAA scientific advice package to the EMA for its cell therapy Ebstrocel in RDEB.
The Biotech Times Editorial Team  · 
Biologics

Beyond Air sells NeuroNOS stake to UNIVO for equity and milestones

Beyond Air is offloading its 58% stake in Israeli neuro-oncology spinout NeuroNOS to TASE-listed UNIVO in exchange for a 19.99% shareholding and
Beyond Air is offloading its 58% stake in Israeli neuro-oncology spinout NeuroNOS to TASE-listed UNIVO in exchange for a 19.99% shareholding and
The Biotech Times Editorial Team  · 
Biotech

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech

Taranis Capital, The Fintech Times and Co-Labs Global have partnered to accelerate FinTech, AI, RegTech and BioTech growth through capital, media and collaboration.

Strategic collaboration combines capital, media reach and collaborative services to cut through market noise and enable faster, safer and more resilient innovation for those who need it most.

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech  · 
Biotech

UK robotics hits $258M in 2026 YTD funding; Cambridge leads all-time

Tracxn data show UK consumer robotics attracted $258M year-to-date in 2026, with Cambridge accounting for nearly 60% of all-time funding at $1
Tracxn data show UK consumer robotics attracted $258M year-to-date in 2026, with Cambridge accounting for nearly 60% of all-time funding at $1
The Biotech Times Editorial Team  · 
Biologics

AC Immune NLRP3 inhibitor clears Phase 1 with CSF penetration

ACI-19764 was safe and well tolerated across dose cohorts, with brain penetration confirmed and a therapeutic dose expected at 10mg once daily.
ACI-19764 was safe and well tolerated across dose cohorts, with brain penetration confirmed and a therapeutic dose expected at 10mg once daily.
The Biotech Times Editorial Team  · 
Biologics

J&J wins EC approval for teclistamab plus daratumumab in RRMM

The European Commission has approved the bispecific-antibody doublet for relapsed/refractory myeloma from second line, backed by Phase 3 survival data.
The European Commission has approved the bispecific-antibody doublet for relapsed/refractory myeloma from second line, backed by Phase 3 survival data.
The Biotech Times Editorial Team  · 
Biologics

VarmX enrols first patient in Phase 3 trial of FXa reversal agent

VarmX has begun enrolling patients in EquilibriX-S, its pivotal Phase 3 study of VMX-C001 for urgent surgery in patients on Factor Xa inhibitors.
VarmX has begun enrolling patients in EquilibriX-S, its pivotal Phase 3 study of VMX-C001 for urgent surgery in patients on Factor Xa inhibitors.
The Biotech Times Editorial Team  · 
Digital Health

Radar Healthcare acquires Cemplicity in patient outcomes push

Radar Healthcare has bought patient experience platform Cemplicity to link PREMs and PROMs data with its quality and safety workflows.
Radar Healthcare has bought patient experience platform Cemplicity to link PREMs and PROMs data with its quality and safety workflows.
The Biotech Times Editorial Team  · 
Biotech
Digital Health
Bioinformatics

UK AI funding hits $9.6bn in H1 2026, up 360% year on year

Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.
Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.
The Biotech Times Editorial Team  · 
Biologics

MiNK Therapeutics reports Day 28 survival data from agenT-797 Phase 2

Early observations from MiNK's randomised Phase 2 in severe hypoxemic pneumonia showed treated patients alive, afebrile and off ventilator support at Day 28.
Early observations from MiNK's randomised Phase 2 in severe hypoxemic pneumonia showed treated patients alive, afebrile and off ventilator support at Day 28.
The Biotech Times Editorial Team  · 
Digital Health

Carvolix secures €30m debt financing from Claret Capital Partners

The French medtech firm will use the growth loan to commercialise TAVIpilot, its FDA-cleared AI-guided software for transcatheter aortic valve procedures.
The French medtech firm will use the growth loan to commercialise TAVIpilot, its FDA-cleared AI-guided software for transcatheter aortic valve procedures.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

Bavarian Nordic wins EC approval of mpox vaccine for young children

IMVANEX is now authorised in the EU for children aged 2 to 11, backed by Phase 2 data showing non-inferior immune responses versus adults.
IMVANEX is now authorised in the EU for children aged 2 to 11, backed by Phase 2 data showing non-inferior immune responses versus adults.
The Biotech Times Editorial Team  · 
Biologics

Novo Nordisk lifts 2026 outlook on stronger GLP-1 sales

The Danish pharma giant raised its full-year adjusted sales and operating profit guidance, citing higher-than-expected demand for its GLP-1 product portfolio.
The Danish pharma giant raised its full-year adjusted sales and operating profit guidance, citing higher-than-expected demand for its GLP-1 product portfolio.
The Biotech Times Editorial Team  · 
Subscribe to UK & Europe